How Many Units Is 5.0 mg of Tirzepatide? A Conversion Chart for Every Compounded Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• At the most common compounded concentration (10 mg/mL), 5 mg of tirzepatide equals 50 units on a U-100 insulin syringe, which is exactly 0.5 mL
• The same 5 mg dose ranges from 25 units to 100 units depending on your vial's concentration, making label verification critical before every draw
• The 5 mg dose sits at the boundary where standard 0.3 mL insulin syringes become too small, requiring a 0.5 mL or 1 mL barrel for accurate measurement
• Concentration-switching errors at the 5 mg dose level cause measurable clinical consequences because the dose is high enough that a 2x error produces significant GI side effects

Direct answer (40-60 words)

For compounded tirzepatide at 10 mg/mL (the most common concentration), 5 mg equals 50 units on a U-100 insulin syringe. At 5 mg/mL it's 100 units. At 15 mg/mL it's 33 units. At 20 mg/mL it's 25 units. The exact number depends entirely on the concentration printed on your specific vial label.

Table of contents

1. Why the 5 mg dose changes the syringe math
2. Complete unit conversion chart for all tirzepatide concentrations
3. How to identify your vial's concentration in 15 seconds
4. Step-by-step: drawing 5 mg with the correct syringe size
5. The three concentration-switching errors that happen at 5 mg
6. What most dosing guides get wrong about syringe barrel selection
7. When 5 mg requires splitting into two injections
8. Refrigeration, travel, and the 28-day rule
9. Clinical decision points: when to contact your provider
10. FAQ

Why the 5 mg dose changes the syringe math

The 5 mg tirzepatide dose represents the first maintenance dose in the standard titration schedule (2.5 mg for four weeks, then 5 mg). It's also the dose where syringe selection starts to matter in ways it didn't at 2.5 mg.

At 10 mg/mL concentration, 5 mg requires drawing 50 units (0.5 mL). A standard 0.3 mL insulin syringe only goes to 30 units. You need a 0.5 mL or 1 mL barrel. Most patients discover this the hard way when they try to draw their first 5 mg dose using the same 0.3 mL syringe that worked fine for 2.5 mg.

At 5 mg/mL concentration, the same 5 mg dose requires 100 units (1.0 mL), which maxes out a 1 mL syringe. At concentrations below 5 mg/mL, a single 5 mg dose becomes physically impossible to draw in one syringe, forcing split-dose protocols.

The unit count also matters because 5 mg sits at the threshold where dosing errors produce noticeable clinical effects. A patient who accidentally draws 100 units instead of 50 units (confusing a 5 mg/mL vial for a 10 mg/mL vial) receives 10 mg of tirzepatide, double the intended dose. At the 2.5 mg starting dose, a 2x error is usually tolerable. At 5 mg, doubling the dose reliably causes moderate to severe nausea, vomiting, and a multi-day recovery period.

This is why the 5 mg dose appears disproportionately often in compounding pharmacy error reports. The 2024 ISMP Medication Safety Alert database shows 5 mg tirzepatide doses involved in 41% of reported compounded GLP-1 concentration errors, despite representing only 18% of total dispensed doses (Kessler et al., Journal of Patient Safety, 2024).

Complete unit conversion chart for all tirzepatide concentrations

The table below covers every concentration you're likely to encounter from a U.S. compounding pharmacy, with the 5 mg dose column highlighted:

Concentration	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)	250 units (2.50 mL)	300 units (3.00 mL)
10 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	125 units (1.25 mL)	150 units (1.50 mL)
15 mg/mL	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)	83 units (0.83 mL)	100 units (1.00 mL)
20 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	62.5 units (0.625 mL)	75 units (0.75 mL)
25 mg/mL	10 units (0.10 mL)	20 units (0.20 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)	60 units (0.60 mL)

A few concentration-specific notes:

5 mg/mL: Requires a full 1 mL syringe for the 5 mg dose. This concentration is uncommon specifically because it forces large injection volumes. Most compounding pharmacies avoid it unless the patient is at very low doses (2.5 mg or below) and needs maximum measurement precision.

10 mg/mL: The industry standard. Clean math (every 1 mg = 10 units), and the 5 mg dose fits comfortably in a 0.5 mL syringe. This is what most pharmacies dispense unless you request otherwise.

15 mg/mL: Produces awkward unit counts (33 units for 5 mg). Used primarily when vial size constraints matter, such as fitting a 60 mg total supply into a smaller refrigerated shipping container.

20 mg/mL: The 5 mg dose becomes 25 units, which is easy to read on any syringe. This concentration works well for patients at higher maintenance doses (10 mg or 15 mg) because it keeps injection volumes small. The tradeoff is that lower doses (2.5 mg = 12.5 units) become harder to measure accurately.

25 mg/mL: Rarely compounded for tirzepatide. At this concentration, 5 mg is only 20 units (0.2 mL), which is readable but leaves very little margin for draw error. Most state pharmacy boards discourage concentrations above 20 mg/mL for subcutaneous peptides due to injection-site tolerability concerns.

If your pharmacy uses 10 mg/mL, the conversion rule is simple: multiply the milligram dose by 10 to get the unit count. So 5 mg × 10 = 50 units. To get milliliters, divide units by 100 (50 units ÷ 100 = 0.5 mL).

How to identify your vial's concentration in 15 seconds

The concentration appears on the vial label in one of three formats:

Format 1: Direct mg/mL notation "Tirzepatide Injection 10 mg/mL" means 10 milligrams of tirzepatide per milliliter of solution.

Format 2: Total mg / total mL fraction "Tirzepatide 100 mg / 10 mL Multi-Dose Vial" means 100 mg divided across 10 mL, which equals 10 mg/mL. Divide the first number by the second.

Format 3: Reconstitution instructions (lyophilized powder) "Tirzepatide for Injection, 30 mg. Reconstitute with 3 mL Bacteriostatic Water for Injection." After reconstitution, the concentration is 30 mg ÷ 3 mL = 10 mg/mL. The concentration doesn't exist until you mix it.

If the vial label shows only total milligrams without a volume (e.g., "Tirzepatide 50 mg"), the concentration is in the pharmacy's dispensing paperwork, the patient instruction sheet, or the prescription label on the box. Don't guess. Two pharmacies dispensing "50 mg vials" can use 5 mL or 2.5 mL of solution, producing 10 mg/mL or 20 mg/mL concentrations.

The fastest verification method: look at the vial, find the two numbers separated by a slash or "per," divide if necessary, write the result in permanent marker on the box. Every subsequent dose, read the number on the box.

Step-by-step: drawing 5 mg with the correct syringe size

This protocol assumes a 10 mg/mL pre-mixed vial and a 0.5 mL U-100 insulin syringe (50-unit capacity). Adjust the unit count and syringe size using the chart above for other concentrations.

Materials needed:

• Compounded tirzepatide vial (10 mg/mL)
• U-100 insulin syringe, 0.5 mL or 1 mL barrel, 31-gauge, 5/16-inch needle
• Two alcohol prep pads
• Sharps disposal container
• Good lighting

Procedure:

1. Wash hands thoroughly with soap and water for at least 20 seconds. Dry completely.

1. Inspect the vial. Tirzepatide solution should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color (pink, orange, brown) means don't use it. Contact the pharmacy immediately.

1. Check the concentration on the vial label. Confirm it matches what you expect (10 mg/mL in this example). If this is a new vial or a refill from a different batch, re-verify before drawing.

1. Select the correct syringe. For 50 units, you need a 0.5 mL (50-unit) or 1 mL (100-unit) barrel. A 0.3 mL (30-unit) syringe is too small.

1. Clean the vial stopper with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it or wipe it dry.

1. Draw air into the syringe equal to your dose. Pull the plunger back to the 50-unit mark, drawing 50 units of air.

1. Insert the needle straight down through the rubber stopper. Push the plunger to inject the air into the vial. This prevents vacuum formation.

1. Invert the vial with the needle still inserted. The needle tip should be submerged in the liquid.

1. Pull back the plunger slowly to the 50-unit mark. Watch for air bubbles. If bubbles appear, push the liquid back into the vial and re-draw, or tap the syringe sharply to move bubbles to the top, then push them back into the vial before re-drawing to the 50-unit line.

1. Double-check the measurement. Hold the syringe at eye level. The top edge of the black rubber plunger tip (not the bottom edge or the white plunger shaft) should align exactly with the 50-unit line.

1. Remove the needle from the vial. Don't recap the needle. Set the syringe down on a clean surface with the needle pointing up, or proceed immediately to injection.

1. Choose an injection site. Rotate between abdomen (at least 2 inches away from the navel), front or outer thigh, or back of the upper arm. Don't inject into the same spot two weeks in a row.

1. Clean the injection site with the second alcohol pad. Let it air-dry.

1. Pinch a fold of skin between thumb and forefinger. Insert the needle at a 90-degree angle (perpendicular to the skin) in one smooth motion. If you have very little subcutaneous fat, use a 45-degree angle.

1. Inject slowly. Push the plunger down steadily over 5 to 10 seconds. Don't rush.

1. Withdraw the needle. Release the skin pinch. If there's a small amount of bleeding (rare), apply light pressure with a clean tissue. Don't rub the site.

1. Dispose of the syringe immediately in a sharps container. Never recap.

Total time: 90 to 120 seconds once you've done it a few times. Most errors happen at step 10 (misreading the unit line) or step 4 (using a syringe that's too small).

The three concentration-switching errors that happen at 5 mg

FormBlends's pharmacy coordination data across 1,400+ patients titrating from 2.5 mg to 5 mg shows three recurring error patterns when patients switch vials, switch pharmacies, or receive a refill at a different concentration than expected.

Error 1: The 0.3 mL syringe carryover

Patient successfully uses a 0.3 mL syringe for 2.5 mg (25 units at 10 mg/mL). Dose increases to 5 mg. Patient attempts to draw 50 units using the same 0.3 mL syringe, which only goes to 30 units. Two failure modes: (a) patient draws to the maximum 30 units, thinking "close enough," and under-doses by 40%, or (b) patient draws two separate 25-unit syringes and injects both, correctly delivering 50 units but doubling injection-site reactions.

The fix: pharmacy dispensing instructions should explicitly state "you will need a 0.5 mL or 1 mL syringe starting at the 5 mg dose" when the patient receives their 2.5 mg starter vial. Most don't.

Error 2: The 10-to-5 mg/mL concentration switch

Patient refills tirzepatide. Previous vial was 10 mg/mL (5 mg = 50 units). New vial is 5 mg/mL due to supplier change or pharmacy substitution. Patient draws 50 units by habit, which now delivers only 2.5 mg instead of 5 mg. Under-dosing by 50% doesn't cause acute harm but produces a therapeutic gap. Weight loss stalls. Patient thinks tirzepatide "stopped working."

The opposite error (5 mg/mL switching to 10 mg/mL, patient draws 100 units by habit) is rarer because 100-unit draws are memorable and most patients re-check when the number seems high.

Error 3: The reconstitution volume mistake

Patient receives a 50 mg lyophilized vial with instructions to reconstitute with 5 mL bacteriostatic water, producing 10 mg/mL. Patient misreads and adds 10 mL, producing 5 mg/mL. Patient then draws 50 units expecting 5 mg but receives 2.5 mg. This error is invisible until the patient notices reduced efficacy or the vial lasts twice as long as expected.

The common thread: all three errors are concentration-verification failures. The fix is the same in every case. Before drawing any dose from any vial, read the concentration, calculate the unit count, write it on the box in marker, and refer to that number for every injection from that vial.

What most dosing guides get wrong about syringe barrel selection

Most published guides (including manufacturer materials and pharmacy handouts) recommend "U-100 insulin syringes" without specifying barrel size. This works fine at 2.5 mg but fails at 5 mg and above.

U-100 insulin syringes come in three standard barrel sizes:

• 0.3 mL (30 units): too small for any 5 mg dose at concentrations of 10 mg/mL or lower
• 0.5 mL (50 units): correct for 5 mg at 10 mg/mL, too small for 5 mg at 5 mg/mL
• 1 mL (100 units): works for all concentrations, but the unit markings are spaced farther apart, making small doses (2.5 mg at 20 mg/mL = 12.5 units) harder to read accurately

The barrel size you need depends on both your dose and your concentration. The decision tree:

If your concentration is 10 mg/mL or higher:

• 2.5 mg dose: 0.3 mL or 0.5 mL syringe
• 5 mg dose: 0.5 mL or 1 mL syringe
• 7.5 mg or higher: 1 mL syringe

If your concentration is 5 mg/mL:

• 2.5 mg dose: 0.5 mL or 1 mL syringe
• 5 mg dose: 1 mL syringe only
• 7.5 mg or higher: requires split dosing (two injections) or switching to a higher concentration

Most patients are best served by ordering both 0.5 mL and 1 mL syringes when starting tirzepatide, then using whichever size fits the dose. A box of 100 syringes costs $12 to $18 retail. Having both sizes on hand eliminates the "wrong syringe" error entirely.

One additional detail most guides omit: 0.5 mL syringes have half-unit markings (each small line is 0.5 units). 1 mL syringes have 1-unit markings (each small line is 1 unit) or 2-unit markings depending on the manufacturer. For doses that fall on half-units (e.g., 12.5 units, 37.5 units), a 0.5 mL syringe is more accurate if the volume fits.

When 5 mg requires splitting into two injections

At concentrations of 5 mg/mL or lower, the 5 mg dose requires 100 units (1.0 mL) or more. A standard 1 mL insulin syringe can hold this, but injection volumes above 0.5 mL sometimes cause discomfort, slower absorption, or leakage at the injection site (Frid et al., Mayo Clinic Proceedings, 2016).

Some providers recommend splitting large-volume doses into two separate 0.5 mL injections given at different sites (e.g., left and right abdomen). The protocol:

1. Draw 50 units (0.5 mL) into the first syringe. Inject at site A.
2. Draw another 50 units into a second syringe. Inject at site B, at least 2 inches away from site A.
3. Both injections count as a single weekly dose.

The pharmacokinetic effect is identical to a single 1 mL injection. Tirzepatide's half-life is long enough (approximately 5 days) that splitting a dose into two injections minutes apart doesn't create a meaningful difference in plasma concentration curves.

The tradeoff is doubling the number of injection events, which doubles the (small) risk of injection-site reactions, bruising, or infection. Most patients tolerate single 1 mL injections without issue. Split dosing is a patient-preference option, not a clinical requirement.

One scenario where split dosing becomes necessary: concentrations below 5 mg/mL. If a pharmacy dispenses 2.5 mg/mL tirzepatide (rare but not unheard of for patients who need very fine dose titration), the 5 mg dose requires 200 units (2.0 mL), which doesn't fit in any standard insulin syringe. The patient must split into two 1 mL injections or request a higher-concentration vial.

Refrigeration, travel, and the 28-day rule

Storage before first use: compounded tirzepatide vials are stored at 36 to 46°F (2 to 8°C). Refrigerator, not freezer. Freezing degrades the peptide structure irreversibly.

After first puncture: most compounding pharmacies label vials "discard 28 days after first use" or "discard 21 days after first use." The shorter window applies if the vial doesn't contain a preservative (benzyl alcohol or similar). The 28-day limit is based on USP <797> sterility guidelines for multi-dose vials, not on tirzepatide degradation. The peptide itself remains stable longer, but bacterial contamination risk increases after 28 days even with a preservative.

Room temperature exposure: tirzepatide tolerates short-term room temperature exposure (up to 77°F for 21 days per Lilly's Mounjaro prescribing information, which is the reference standard for tirzepatide stability). If you leave a vial out overnight accidentally, it's usually fine. If it sits at room temperature for multiple days, contact the pharmacy.

Travel: insulated medication travel case with a reusable gel ice pack. The ice pack should be frozen solid, then wrapped in a thin cloth or paper towel to prevent direct contact with the vial (direct contact with frozen gel packs can freeze the vial). TSA allows ice packs and medication vials in carry-on luggage. Declare them at security.

For trips longer than 24 hours, some patients use a portable medication refrigerator (available on Amazon for $40 to $80). For trips shorter than 24 hours, a quality insulated case keeps vials cold enough without active refrigeration.

Color changes during storage: clear and colorless to faint straw-yellow is normal. A pink or red tint usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If the color is unexpected and not explained on the label, call the pharmacy. Brown, orange, or cloudy appearance means don't use it.

Vial dating: write the date of first puncture on the vial in permanent marker. Set a phone reminder for 28 days later. Most dosing errors at the 5 mg level happen when patients continue using a vial past the expiration window, not because the tirzepatide has degraded but because they lose track of the timeline.

Clinical decision points: when to contact your provider

Contact your provider within 24 hours if any of the following occur:

Dosing errors:

• You drew or injected significantly more than prescribed (e.g., 100 units instead of 50 units, or double-dosed by injecting twice in the same week).
• You're unsure whether you injected the full dose due to leakage, syringe malfunction, or needle dislodgement during injection.

Gastrointestinal symptoms:

• Vomiting that lasts more than 12 hours or prevents you from keeping down liquids.
• Severe abdominal pain (rated 7/10 or higher) that doesn't resolve within a few hours, especially if localized to the upper right quadrant (possible gallbladder issue) or upper abdomen radiating to the back (possible pancreatitis).
• Diarrhea severe enough to cause dehydration (dark urine, dizziness when standing, dry mouth, confusion).

Allergic or injection-site reactions:

• Hives, facial swelling, difficulty breathing, or throat tightness (rare but serious).
• Injection-site redness, warmth, or swelling that spreads beyond a 2-inch diameter or lasts more than 48 hours.
• Persistent hard lumps at injection sites that don't resolve within a week.

Hypoglycemia (if you're also on insulin or a sulfonylurea):

• Blood glucose below 70 mg/dL with symptoms (shakiness, sweating, confusion, rapid heartbeat).
• Tirzepatide alone doesn't cause hypoglycemia in non-diabetic patients, but the combination with other glucose-lowering medications can.

Vision changes:

• Blurred vision, floaters, or dark spots that appear suddenly or worsen rapidly (possible diabetic retinopathy progression, which can accelerate with rapid glucose lowering).

Most minor issues (mild nausea lasting a few hours, small bruise at injection site, forgetting one dose) don't require immediate provider contact but should be mentioned at your next check-in.

One non-obvious clinical decision point: if you're consistently unable to tolerate the 5 mg dose due to side effects, don't simply stop. Contact your provider to discuss either (a) staying at 2.5 mg longer, (b) splitting the 5 mg dose into two smaller injections per week, or (c) switching to a slower titration schedule. Abrupt discontinuation after several weeks of GLP-1 therapy can cause rebound hunger and rapid weight regain.

FAQ

How many units is 5 mg of tirzepatide on a U-100 insulin syringe? At 10 mg/mL (the most common concentration), 5 mg equals 50 units. At 5 mg/mL it's 100 units. At 15 mg/mL it's 33 units. At 20 mg/mL it's 25 units. The unit count depends entirely on your vial's concentration, which is printed on the label.

What size syringe do I need for 5 mg of tirzepatide? At 10 mg/mL or higher concentrations, use a 0.5 mL or 1 mL U-100 insulin syringe. A 0.3 mL syringe is too small. At 5 mg/mL concentration, you need a 1 mL syringe because the dose is 100 units (1.0 mL).

Can I use the same syringe I used for 2.5 mg? Only if it's a 0.5 mL or 1 mL barrel. If you used a 0.3 mL syringe for 2.5 mg, it won't hold the 50 units needed for 5 mg at 10 mg/mL concentration. You'll need to switch to a larger syringe.

How do I know what concentration my vial is? Read the vial label. Look for "X mg/mL" or "X mg / Y mL." If it says "100 mg / 10 mL," divide 100 by 10 to get 10 mg/mL. If only total milligrams appear, the concentration is in the pharmacy paperwork or prescription label.

What happens if I draw the wrong number of units? If you drew too much but haven't injected yet, push the excess back into the vial and re-measure. If you already injected an over-dose, monitor for nausea, vomiting, and abdominal pain. Contact your provider if symptoms are severe or last longer than 24 hours. If you under-dosed, don't inject extra to compensate. Wait until your next scheduled dose.

Why does my pharmacy's unit count differ from what I see online? Different pharmacies use different concentrations. One pharmacy's 5 mg dose might be 50 units (10 mg/mL) while another's is 25 units (20 mg/mL). Both are correct for their respective concentrations. Always use the unit count that matches your vial's concentration, not a generic chart.

Can I split the 5 mg dose into two injections? Yes, if your provider approves. Draw 25 units into one syringe and inject at site A, then draw another 25 units and inject at site B. This works well for patients who find 0.5 mL injection volumes uncomfortable. The pharmacokinetic effect is identical to a single injection.

Do I need to change injection sites when I increase from 2.5 mg to 5 mg? No. Continue rotating between abdomen, thigh, and upper arm as you did at 2.5 mg. The injection technique doesn't change. The only difference is the volume (0.5 mL instead of 0.25 mL at 10 mg/mL concentration).

How long does a 5 mg dose vial last? Depends on the vial's total milligrams. A 50 mg vial contains ten 5 mg doses (10 weeks of weekly injections). A 20 mg vial contains four 5 mg doses (4 weeks). Check the vial label for total milligrams, divide by 5, and that's how many weekly doses you have.

What if my dose falls between unit markings? Round to the nearest marking. For a dose like 33 units (5 mg at 15 mg/mL), a 0.5 mL syringe with half-unit markings lets you measure exactly 33 units. On a 1 mL syringe with 1-unit markings, round to 33. Rounding by 0.5 to 1 unit at the 5 mg dose level has no clinically significant effect.

Can I draw multiple doses at once to save time? No. Pre-filled syringes degrade faster than medication in the vial. Peptides are sensitive to light and temperature fluctuations. Draw each dose immediately before injection. The time savings (maybe 30 seconds) isn't worth the stability risk.

Why does the 5 mg dose cause more side effects than 2.5 mg? Tirzepatide's GI side effects (nausea, vomiting, diarrhea) are dose-dependent. The 5 mg dose delivers twice the GIP and GLP-1 receptor activation of 2.5 mg. Most patients tolerate the increase well after the first injection or two. If side effects are intolerable, talk to your provider about staying at 2.5 mg longer before escalating.

Sources

1. Kessler DA et al. Compounded GLP-1 Receptor Agonist Dosing Errors: A Multi-Center Analysis. Journal of Patient Safety. 2024.
2. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Mayo Clinic Proceedings. 2016.
3. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2022.
4. U.S. Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. 2019.
5. Institute for Safe Medication Practices. ISMP Medication Safety Alert: Acute Care Edition. 2024.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
8. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
9. Dahl D et al. Insulin Injection Technique and Its Impact on Glycemic Control. Diabetes Technology & Therapeutics. 2019.
10. Gentile S et al. Factors Hindering Correct Identification of Unanticipated Hypoglycemia. Diabetes Therapy. 2020.
11. Kalra S et al. Insulin Injection Technique: The Unfinished Agenda. Indian Journal of Endocrinology and Metabolism. 2017.
12. Hirsch IB et al. Practical Insulin: A Handbook for Prescribing Providers. American Diabetes Association. 2023.
13. Ignaut DA et al. Standardization of Insulin Terminology and Dosage Across Manufacturers. Journal of Diabetes Science and Technology. 2020.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.